CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 24 enrolled
Drug / intervention
everlinQ endoAVF Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03708562
NCT03708562N/ACompleted
CompareCT.gov

everlinQ Endovascular Access Systems Enhancements (EASE-2) Study

C. R. Bard·interventional·Posted Oct 17, 2018·Updated Dec 11, 2025

In Brief

A clinical study evaluating everlinQ endoAVF System for Chronic Kidney Diseases. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Prospective, single-center study to evaluate the everlinQ endoAVF System when used to create an endoAVF in hemodialysis patients. This study aims to investigate expansion of the percutaneous venous access location to the superficial system which may provide additional procedural benefit.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Diseases
CountriesParaguay
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedOct 17, 2018
Enrollment StartOct 16, 2017
Primary CompletionDec 12, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.7 years ago

Interventions

everlinQ endoAVF Systemdevice

The everlinQ device is a single-use disposable device. The everlinQ catheter system consists of two flexible, magnetic catheters. Once the catheters are properly inserted and aligned, the magnets contained in each catheter attract to one another, approximating the vessels while simultaneously aligning the electrode with the backstop. Radiofrequency (RF) energy is delivered to the electrode whereby the arterio-venous fistula (AVF) is created.